SYN-Tech Chem & Pharm Co Ltd (1777) - Total Assets
Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) holds total assets worth NT$2.96 Billion TWD (≈ $93.25 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SYN-Tech Chem & Pharm Co Ltd (1777) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
SYN-Tech Chem & Pharm Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See 1777 book value for net asset value and shareholders' equity analysis.
SYN-Tech Chem & Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
SYN-Tech Chem & Pharm Co Ltd's total assets of NT$2.96 Billion consist of 51.7% current assets and 48.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 35.4% |
| Accounts Receivable | NT$113.86 Million | 3.9% |
| Inventory | NT$340.46 Million | 11.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 1777 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SYN-Tech Chem & Pharm Co Ltd's current assets represent 51.7% of total assets in 2025, a decrease from 66.5% in 2015.
- Cash Position: Cash and equivalents constituted 35.4% of total assets in 2025, up from 30.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
SYN-Tech Chem & Pharm Co Ltd Competitors by Total Assets
Key competitors of SYN-Tech Chem & Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
SYN-Tech Chem & Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.03 | 6.08 | 2.20 |
| Quick Ratio | 3.91 | 3.78 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.23 Billion | NT$1.11 Billion | NT$557.39 Million |
SYN-Tech Chem & Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between SYN-Tech Chem & Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | NT$2.96 Billion |
| Market Capitalization | $101.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values SYN-Tech Chem & Pharm Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SYN-Tech Chem & Pharm Co Ltd's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SYN-Tech Chem & Pharm Co Ltd (2015–2025)
The table below shows the annual total assets of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$2.96 Billion ≈ $93.25 Million |
+3.79% |
| 2024-12-31 | NT$2.85 Billion ≈ $89.85 Million |
-1.69% |
| 2023-12-31 | NT$2.90 Billion ≈ $91.39 Million |
+4.37% |
| 2022-12-31 | NT$2.78 Billion ≈ $87.57 Million |
-3.99% |
| 2021-12-31 | NT$2.90 Billion ≈ $91.21 Million |
+62.46% |
| 2020-12-31 | NT$1.78 Billion ≈ $56.14 Million |
-4.25% |
| 2019-12-31 | NT$1.86 Billion ≈ $58.63 Million |
+1.99% |
| 2018-12-31 | NT$1.82 Billion ≈ $57.49 Million |
+17.28% |
| 2017-12-31 | NT$1.56 Billion ≈ $49.02 Million |
+20.85% |
| 2016-12-31 | NT$1.29 Billion ≈ $40.56 Million |
+5.17% |
| 2015-12-31 | NT$1.22 Billion ≈ $38.57 Million |
-- |
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more